# FDA recall D-0251-2026

> **Imprimis NJOF, LLC** · Class II · drug recall initiated 2025-12-18.

## Product

Tri-Moxi+¿  (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

## Reason for recall

Presence of particulate matter - Glass like particles.

## Distribution

U.S Nationwide

## Key facts

- **Recall number:** D-0251-2026
- **Recalling firm:** Imprimis NJOF, LLC
- **Classification:** Class II
- **Product type:** drug
- **Status:** Ongoing
- **Initiation date:** 2025-12-18
- **Report date:** 2026-01-14

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Ledgewood, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0251-2026

## Citation

> AI Analytics. FDA recall D-0251-2026. Retrieved 2026-06-25 from https://api.ai-analytics.org/recall/D-0251-2026. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*